Beau Brouillette
Family Medicine · Marksville, LANPI 1457353682
Payments from drug & device makers
Across 418 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$968
- Novo Nordisk$793
- AbbVie$591
- Lilly USA, LLC$463
- Takeda Pharmaceuticals U.S.A., Inc.$415
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,837100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $1,193 |
| GSK | 82 | $968 |
| Novo Nordisk | 54 | $793 |
| AbbVie(2 entities) | 30 | $591 |
| Lilly USA, LLC | 38 | $463 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $415 |
| Merck | 23 | $392 |
| Amgen | 20 | $331 |
| Pfizer | 24 | $280 |
| Sanofi-aventis U.S. LLC | 13 | $203 |
| Mylan Specialty L.p. | 4 | $161 |
| Boston Scientific | 2 | $159 |
| Boehringer Ingelheim | 9 | $135 |
| Johnson & Johnson | 7 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Exact Sciences | 4 | $63 |
| Neurocrine Biosciences, Inc. | 3 | $58 |
| Abbott | 3 | $53 |
| Acadia Pharmaceuticals Inc | 3 | $41 |
| Novartis | 2 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$231
- AIRSUPRA$121
- Ozempic$116
- FARXIGA$112
- GENERAL - THERAPIES$100
How this compares
$6,852 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 244 | $303,627 |
| FarxigaDapagliflozin Propanediol | 305 | $272,494 |
| OzempicSemaglutide | 233 | $263,493 |
| JardianceEmpagliflozin | 177 | $203,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 191 | $193,858 |
| Tresiba Flextouch U-200Insulin Degludec | 110 | $123,170 |
| RybelsusSemaglutide | 58 | $95,578 |
| EliquisApixaban | 102 | $91,335 |
| TrulicityDulaglutide | 89 | $89,678 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $83,097 |
| LinzessLinaclotide | 94 | $73,778 |
| XareltoRivaroxaban | 76 | $72,338 |
| TrintellixVortioxetine Hydrobromide | 82 | $58,257 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $47,000 |
| MyrbetriqMirabegron | 57 | $40,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $463 | $393,304333 claims |
| Novo NordiskOzempic, Rybelsus | $793 | $359,072291 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,193 | $319,494371 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $135 | $225,715203 claims |
| GSKTrelegy Ellipta | $968 | $193,858191 claims |
| AbbVieLinzess, Vraylar, Viberzi, Ubrelvy | $591 | $134,145136 claims |
| PfizerEliquis | $280 | $91,335102 claims |
| Johnson & JohnsonXarelto | $98 | $72,33876 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $415 | $58,25782 claims |
| MerckJanuvia, Janumet | $392 | $40,69447 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $40,02857 claims |
| NovartisEntresto | $31 | $21,67820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Marksville
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.